AVITA Medical interim results show significant reduction in skin grafting timelines
AVITA Medical (NASDAQ:RCEL) announced on Tuesday, April 14, 2026, positive interim results from its Cohealyx-I clinical study, demonstrating that its dermal matrix significantly accelerates the timeline for skin grafting in complex wounds.










